Stockreport
Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF
MELBOURNE, Australia and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with an update on its corporate strategy, operational highlights, and consolidated financial results for the three months ended September 30, 2017 (first quarter of FY2018). At September 30, 2017, the Company had cash reserves of US$62.9 million. Cash outflows from operating activities were reduced by US$0.5m (2.3%) for the quarter as compared to the three months ended September 30, 2016 (first quarter of FY2017). Based on cumulative clinical results to date and the serious and life-threatening nature of the diseases being targeted, the Company believes that its Phase 3 product candidates for acute graft versus host disease (aGVHD), chronic heart failure, and chronic low back pain may represent a paradigm shift in the treatment of these conditions which can lead to earlier market entry due to opportunities afforded by the United States 21st Cent
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MESO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MESO alerts
MESO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting MESOBLAST LTD ADS news events
Weekly update
A roundup of the hottest topics
MESO
NEWS
NEWS
- Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure[GlobeNewswire]
- Mesoblast limited (NASDAQ: MESO) was given a new $14.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock.[MarketBeat]
- Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment[GlobeNewswire]
- Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Credit Suisse Group AG from a "neutral" rating to an "underperform" rating.[MarketBeat]
- Mesoblast limited (NASDAQ: MESO) was given a new $14.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock.[MarketBeat]
- More